VGX International to initiate Phase I clinical studies of VGX-1027

Published: 2008-01-16 06:56:00

Updated: 2008-01-16 06:56:00

VGX International is planning to conduct its Phase I clinical studies of VGX-1027, a novel small molecule compound with potent anti-inflammatory activity, in healthy volunteers jointly with its affiliate, VGX Pharmaceuticals after getting the approval of an investigational new drug (IND) applicat...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK